Skip to main content

7 Result(s)

within N Chapuis Remove this filter Internal Medicine Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling

    G Kerdivel, V Chesnais, E Becht, A Toma, N Cagnard, F Dumont, A Rousseau… in Leukemia (2018)

  2. No Access

    Article

    High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells

    Alterations in metabolic activities are cancer hallmarks that offer a wide range of new therapeutic opportunities. Here we decipher the interplay between mTORC1 activity and glucose metabolism in acute myeloid...

    L Poulain, P Sujobert, F Zylbersztejn, S Barreau, L Stuani, M Lambert… in Leukemia (2017)

  3. No Access

    Article

    Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes

    Several groups have published flow cytometry scores useful for the diagnosis or prognosis of myelodysplastic syndromes (MDS), mainly based on the detection of immunophenotypic abnormalities in the maturation o...

    S Mathis, N Chapuis, C Debord, A Rouquette, I Radford-Weiss, S Park, F Dreyfus… in Leukemia (2013)

  4. No Access

    Article

    A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse

    The mTORC1 signaling pathway is constitutively activated in almost all acute myelogenous leukemia (AML) patients. We conducted a phase Ib trial combining RAD001 (everolimus), an allosteric inhibitor of mTORC1,...

    S Park, N Chapuis, F Saint Marcoux, C Recher, T Prebet, P Chevallier, J-Y Cahn… in Leukemia (2013)

  5. No Access

    Article

    The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

    The serine/threonine kinase mammalian target of rapamycin (mTOR) is crucial for cell growth and proliferation, and is constitutively activated in primary acute myeloid leukemia (AML) cells, therefore represent...

    L Willems, N Chapuis, A Puissant, T T Maciel, A S Green, N Jacque, C Vignon… in Leukemia (2012)

  6. No Access

    Article

    Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

    Mammalian target of rapamycin (mTOR) is a protein kinase implicated in the regulation of various cellular processes, including those required for tumor development, such as the initiation of mRNA translation, ...

    N Chapuis, J Tamburini, A S Green, L Willems, V Bardet, S Park, C Lacombe… in Leukemia (2010)

  7. No Access

    Article

    PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML

    The phosphatidylinositol 3-kinase (PI3K)/Akt and mammalian target of rapamycin complex 1 (mTORC1) signaling pathways are frequently activated in acute myelogenous leukemia (AML). mTORC1 inhibition with RAD001 ...

    S Park, N Chapuis, V Bardet, J Tamburini, N Gallay, L Willems, Z A Knight… in Leukemia (2008)